QQQ   353.14 (+1.48%)
AAPL   179.84 (+1.46%)
MSFT   333.41 (+1.53%)
META   273.78 (+3.42%)
GOOGL   123.46 (+0.48%)
AMZN   123.34 (+2.29%)
TSLA   209.72 (+2.84%)
NVDA   399.08 (+5.48%)
NIO   7.60 (+0.93%)
BABA   83.25 (+4.65%)
AMD   120.76 (+2.16%)
T   15.83 (+0.64%)
F   12.16 (+1.33%)
MU   69.37 (+1.72%)
CGC   0.83 (-0.26%)
GE   105.12 (+3.54%)
DIS   88.97 (+1.15%)
AMC   4.58 (+1.78%)
PFE   38.06 (+0.11%)
PYPL   63.41 (+2.29%)
NFLX   405.50 (+2.60%)
QQQ   353.14 (+1.48%)
AAPL   179.84 (+1.46%)
MSFT   333.41 (+1.53%)
META   273.78 (+3.42%)
GOOGL   123.46 (+0.48%)
AMZN   123.34 (+2.29%)
TSLA   209.72 (+2.84%)
NVDA   399.08 (+5.48%)
NIO   7.60 (+0.93%)
BABA   83.25 (+4.65%)
AMD   120.76 (+2.16%)
T   15.83 (+0.64%)
F   12.16 (+1.33%)
MU   69.37 (+1.72%)
CGC   0.83 (-0.26%)
GE   105.12 (+3.54%)
DIS   88.97 (+1.15%)
AMC   4.58 (+1.78%)
PFE   38.06 (+0.11%)
PYPL   63.41 (+2.29%)
NFLX   405.50 (+2.60%)
QQQ   353.14 (+1.48%)
AAPL   179.84 (+1.46%)
MSFT   333.41 (+1.53%)
META   273.78 (+3.42%)
GOOGL   123.46 (+0.48%)
AMZN   123.34 (+2.29%)
TSLA   209.72 (+2.84%)
NVDA   399.08 (+5.48%)
NIO   7.60 (+0.93%)
BABA   83.25 (+4.65%)
AMD   120.76 (+2.16%)
T   15.83 (+0.64%)
F   12.16 (+1.33%)
MU   69.37 (+1.72%)
CGC   0.83 (-0.26%)
GE   105.12 (+3.54%)
DIS   88.97 (+1.15%)
AMC   4.58 (+1.78%)
PFE   38.06 (+0.11%)
PYPL   63.41 (+2.29%)
NFLX   405.50 (+2.60%)
QQQ   353.14 (+1.48%)
AAPL   179.84 (+1.46%)
MSFT   333.41 (+1.53%)
META   273.78 (+3.42%)
GOOGL   123.46 (+0.48%)
AMZN   123.34 (+2.29%)
TSLA   209.72 (+2.84%)
NVDA   399.08 (+5.48%)
NIO   7.60 (+0.93%)
BABA   83.25 (+4.65%)
AMD   120.76 (+2.16%)
T   15.83 (+0.64%)
F   12.16 (+1.33%)
MU   69.37 (+1.72%)
CGC   0.83 (-0.26%)
GE   105.12 (+3.54%)
DIS   88.97 (+1.15%)
AMC   4.58 (+1.78%)
PFE   38.06 (+0.11%)
PYPL   63.41 (+2.29%)
NFLX   405.50 (+2.60%)
NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Stock Forecast, Price & News

$64.84
+0.80 (+1.25%)
(As of 03:10 PM ET)
Compare
Today's Range
$62.84
$65.60
50-Day Range
$43.14
$67.77
52-Week Range
$38.94
$86.95
Volume
963,287 shs
Average Volume
1.22 million shs
Market Capitalization
$5.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.89

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
19.1% Upside
$75.05 Price Target
Short Interest
Healthy
16.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of CRISPR Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$2.38 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.61) to ($5.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

895th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

125th out of 330 stocks


CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG is a leading biotechnology company specializing in developing transformative gene-editing therapies. Founded in 2013, the company has quickly emerged as a key player in precision medicine, leveraging the power of CRISPR-Cas9 technology to address a wide range of genetic diseases.

CRISPR Therapeutics aims to develop innovative therapies that harness the potential of gene editing to provide life-changing treatments for patients in need. The company seeks to correct disease-causing mutations at the root level by precisely modifying genes and promising long-lasting and potentially curative therapies.

Headquartered in Zug, Switzerland, with additional offices in the United States, CRISPR Therapeutics operates globally to advance its groundbreaking research and collaborate with partners in the scientific and medical communities. The company's multidisciplinary team of scientists, researchers, and industry experts is dedicated to pushing the boundaries of genetic medicine and revolutionizing patient care.

CRISPR Therapeutics focuses on developing CRISPR-Cas9-based therapies that target specific genetic sequences. The company's pipeline includes a diverse portfolio of investigational treatments for various diseases, including blood disorders, cancer, and rare genetic conditions. The company's lead product candidate, CTX001, aims to treat transfusion-dependent beta-thalassemia and sickle cell disease by editing patients' hematopoietic stem cells. This product candidate has received Orphan Drug Designation from the U.S. FDA and has been designated with Fast Track Designation from the FDA. 

The target market for CRISPR Therapeutics' gene-editing therapies primarily comprises patients suffering from genetic diseases with limited treatment options. The company's focus on hematopoietic stem cells and blood disorders demonstrates its commitment to addressing this field's unmet medical needs. By targeting genetic mutations directly, CRISPR Therapeutics aims to provide personalized and potentially curative treatments for individuals affected by these conditions.

CRISPR Therapeutics boasts a seasoned management team that combines diverse expertise in genetics, drug development, and business strategy. Led by Chief Executive Officer Samarth Kulkarni, Ph.D., the management team has a proven track record of success in the biotech industry. The company's leadership is dedicated to driving scientific innovation, clinical progress, and commercial growth.

Over the past few years, CRISPR Therapeutics has demonstrated mixed financial performance, driven by its groundbreaking research, development efforts and slowed market uncertainty. The company has struggled with reporting revenue growth, reflecting uncertainty in the interest and investment in gene-editing technologies. 

CRISPR Therapeutics' valuation metrics, such as its price-to-earnings and price-to-book ratios, are competitive compared to its industry peers. Investors recognize the potential of CRISPR Therapeutics' gene-editing therapies to revolutionize the treatment of genetic diseases, leading to increased investor sentiment and a positive outlook for the company's stock. 

CRISPR Therapeutics stock has exhibited mixed performance in recent years. The company's shares have experienced significant price movements, reflecting the market's recognition of its innovative approach to gene editing. However, there have been several declines in the stock price due to missed earnings reports and regulatory concerns. 

CRISPR Therapeutics operates within the broader biotechnology industry, which is experiencing rapid advancements and substantial growth potential. The field of gene editing has garnered significant attention due to its ability to target and potentially cure genetic diseases. The industry's growth is fueled by increasing investments in research and development and a growing understanding of the human genome.

Competition within the industry is intense, with several companies vying to develop gene-editing therapies. However, CRISPR Therapeutics has established itself as a leader in the space thanks to its pioneering CRISPR-Cas9 technology and its robust pipeline of product candidates. The company's early clinical trial success and strategic partnerships further strengthen its competitive positioning.

Regulatory and political factors also play a crucial role in shaping the industry. Gene editing is a rapidly evolving field, and regulatory frameworks are being developed to ensure these technologies' ethical and safe application. Changes in regulations or public sentiment regarding gene editing could impact the industry's trajectory and the adoption of gene therapies.

CRISPR Therapeutics has several avenues for growth and expansion. One significant opportunity lies in the advancement of its pipeline and the successful commercialization of its gene-editing therapies. As the company progresses through clinical trials and obtains regulatory approvals, it can potentially bring life-changing treatments to patients worldwide.

While CRISPR Therapeutics has demonstrated significant progress and potential, it is essential to acknowledge the risks and challenges inherent in the biotechnology industry. The company faces scientific, regulatory, and commercialization risks that could impact its future prospects.

Scientific challenges include ensuring the efficacy and safety of gene-editing therapies and addressing potential off-target effects. The complex nature of genetic diseases and the need for long-term follow-up data pose additional hurdles in demonstrating the durability and efficacy of treatments.

Regulatory uncertainties and evolving guidelines can impact the timeline and cost of clinical development and regulatory approval. Changes in regulations or unexpected regulatory hurdles may delay the commercialization of CRISPR Therapeutics' products and hinder market access.

Commercialization challenges include pricing and reimbursement considerations and competition from other companies developing gene therapies. The ability to secure favorable reimbursement terms and navigate complex healthcare systems will be crucial for successfully commercializing CRISPR Therapeutics' therapies.

CRISPR Therapeutics has implemented robust risk management strategies to mitigate these risks and challenges. The company strongly focuses on rigorous scientific research and clinical development, ensuring thorough evaluation of its therapies before advancing them into clinical trials. CRISPR Therapeutics aims to address scientific risks associated with gene editing by prioritizing patient safety and efficacy.

Additionally, CRISPR Therapeutics actively engages with regulatory authorities to stay informed about evolving guidelines and requirements. The company invests in regulatory affairs expertise to navigate the complex regulatory landscape effectively. CRISPR Therapeutics aims to minimize regulatory risks and ensure a smooth path to market approval by proactively collaborating with regulatory agencies and adhering to stringent compliance standards.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (CRSP)
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.3%
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.3%
Stifel Nicolaus Remains a Hold on Crispr Therapeutics AG (CRSP)
Why Are CRISPR Therapeutics Charts Saying 'Buy'?
See More Headlines

CRSP Price History

CRSP Company Calendar

Last Earnings
5/08/2023
Today
6/01/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$74.89
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+16.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
19 Analysts

Profitability

Net Income
$-650,170,000.00
Net Margins
-516.43%
Pretax Margin
-525.28%

Debt

Sales & Book Value

Annual Sales
$1.20 million
Book Value
$23.50 per share

Miscellaneous

Free Float
75,699,000
Market Cap
$5.05 billion
Optionable
Optionable
Beta
1.71

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

19 Wall Street analysts have issued 1 year target prices for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they anticipate the company's share price to reach $74.89 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2023?

CRISPR Therapeutics' stock was trading at $40.65 at the beginning of 2023. Since then, CRSP shares have increased by 57.5% and is now trading at $64.04.
View the best growth stocks for 2023 here
.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 12,430,000 shares, a decrease of 5.8% from the April 30th total of 13,200,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is presently 9.5 days. Currently, 16.4% of the company's stock are sold short.
View CRISPR Therapeutics' Short Interest
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Monday, May, 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.97. The business earned $100 million during the quarter, compared to analysts' expectations of $24.33 million. CRISPR Therapeutics had a negative net margin of 516.43% and a negative trailing twelve-month return on equity of 26.64%. The company's revenue was up 10538.3% on a year-over-year basis. During the same quarter last year, the company posted ($2.32) EPS.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (10.16%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), Nikko Asset Management Americas Inc. (5.04%), BlackRock Inc. (3.55%), FMR LLC (2.71%) and State Street Corp (2.52%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $64.04.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $5.05 billion and generates $1.20 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -